Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors

A method of treating a cancer that expresses IGF-1R comprising administering a complex to an individual with the cancer, wherein the complex comprises:

• (i) an anti-IGF-1R IgG antibody attached to one or more anchor domain (AD) moieties from an AKAP protein;
• and
• (ii) two or more copies of an effector attached to a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the effector is a second antibody fragment, an affibody or a cytokine;
• wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.

A method of treating an autoimmune disease comprising administering a complex to an individual with the autoimmune disease, wherein the complex comprises:

• (i) an anti-IGF-1R IgG antibody attached to one or more anchor domain (AD) moieties from an AKAP protein;
• and
• (ii) two or more copies of an effector attached to a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the effector is a second antibody fragment, an affibody or a cytokine;
• wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.